Skip to Main Content

Paper Details

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nat Med
175
2021
Author NameAffiliation
Christopher B WilsonUniversity of Chicago
Christopher B WilsonUniversity of Chicago
Teresa AydilloIcahn School of Medicine at Mount Sinai
Teresa AydilloGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Lynda CoughlanIcahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreIcahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreIcahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreThe Tisch Cancer Center, Icahn School of Medicine at Mount Sinai
Peter PaleseIcahn School of Medicine at Mount Sinai
Peter PaleseIcahn School of Medicine at Mount Sinai
Peter PaleseThe Tisch Cancer Center, Icahn School of Medicine at Mount Sinai
  • 1 - 12

Datasets

Release 1.2